Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Asia Pacific Pharmacogenomics Market, 2019-2030, $ mn 20
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice 22
Figure 7. Impact of COVID-19 on Business 24
Figure 8. Primary Drivers and Impact Factors of Asia Pacific Pharmacogenomics Market 26
Figure 9. World Top 10 Causes of Deaths, 2016 29
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Pharmacogenomics Market 30
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics 32
Figure 12. Investment Opportunity Analysis 34
Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Pharmacogenomics Market 37
Figure 14. Breakdown of Asia Pacific Pharmacogenomics Market by Service, 2019-2030, % of Revenue 41
Figure 15. Asia Pacific Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%) 42
Figure 16. Asia Pacific Pharmacogenomics Market: Genotyping, 2019-2030, $ mn 43
Figure 17. Asia Pacific Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn 44
Figure 18. Asia Pacific Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn 45
Figure 19. Asia Pacific Pharmacogenomics Market: Other Services, 2019-2030, $ mn 47
Figure 20. Breakdown of Asia Pacific Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue 48
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%) 49
Figure 22. Asia Pacific Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn 50
Figure 23. Asia Pacific Pharmacogenomics Market: Microarray, 2019-2030, $ mn 51
Figure 24. Asia Pacific Pharmacogenomics Market: Sequencing, 2019-2030, $ mn 52
Figure 25. Asia Pacific Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn 53
Figure 26. Asia Pacific Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn 54
Figure 27. Asia Pacific Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn 55
Figure 28. Breakdown of Asia Pacific Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue 56
Figure 29. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 57
Figure 30. Asia Pacific Pharmacogenomics Market: Oncology, 2019-2030, $ mn 58
Figure 31. Asia Pacific Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn 59
Figure 32. Asia Pacific Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn 60
Figure 33. Asia Pacific Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn 62
Figure 34. Asia Pacific Pharmacogenomics Market: Pain Management, 2019-2030, $ mn 63
Figure 35. Asia Pacific Pharmacogenomics Market: Other Applications, 2019-2030, $ mn 64
Figure 36. Breakdown of Asia Pacific Pharmacogenomics Market by End User, 2019-2030, % of Revenue 65
Figure 37. Asia Pacific Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 66
Figure 38. Asia Pacific Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn 67
Figure 39. Asia Pacific Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn 68
Figure 40. Asia Pacific Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn 69
Figure 41. Breakdown of APAC Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 71
Figure 42. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 72
Figure 43. Pharmacogenomics Market in Japan, 2019-2030, $ mn 74
Figure 44. Pharmacogenomics Market in China, 2019-2030, $ mn 76
Figure 45. Pharmacogenomics Market in Australia, 2019-2030, $ mn 78
Figure 46. Pharmacogenomics Market in India, 2019-2030, $ mn 80
Figure 47. Pharmacogenomics Market in South Korea, 2019-2030, $ mn 82
Figure 48. Pharmacogenomics Market in Rest of APAC, 2019-2030, $ mn 84
Figure 49. Growth Stage of Asia Pacific Pharmacogenomics Industry over the Forecast Period 86
Asia Pacific pharmacogenomics market will grow by 10.3% annually with a total addressable market cap of $21.7 billion over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 35 tables and 49 figures, this 122-page report “Asia Pacific Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country. Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Genotyping • SNP Identification • Diagnostics • Other Services Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Polymerase Chain Reaction (PCR) • Microarray • Sequencing • Electrophoresis • Mass Spectrometry • Other Technologies Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oncology • Infectious Diseases • Neurology/Psychiatry • Cardiovascular • Pain Management • Other Applications Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals and Clinics • Pharmaceutical Companies • Research Institutes Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): 23andMe, Inc. Abbott Laboratories Admera Health, LLC Agena Biosciences, Inc. Astra Zeneca PLC Bayer AG Becton, Dickinson and Company Cancer Genetics, Inc. Dynamic DNA Laboratories Empire Genomics LLC F. Hoffmann-La Roche Ltd geneOmbio Technologies Pvt Ltd. Genomic Health, Inc. Illumina, Inc. Laboratory Corporation of America Holdings Myriad Genetics Inc. Oneome LLC Opko Health, Inc. Pathway Genomics Corporation QIAGEN N.V. Quest Diagnostics Incorporated Teva Pharmaceuticals Industries Ltd. Thermo Fisher Scientific Inc. Transgenomic, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More